Consultation on ulcerative colitis drugs
In draft guidance, the National Institute for Health and Care Excellence (NICE) says infliximab, adalimumab and golimumab should not be recommended for routine use in the NHS to treat moderate to severe ulcerative colitis. A consultation on the draft guidance is available on the NICE website until 15 October 2014.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066619
Recommended from Pharmaceutical Press